~~What is c~~Claim~~ed i~~s:

1. Use of an anti-C1q antibody in the manufacture of a medicament for the treatment of ~~A method of treating~~ an ocular disease in a human patient, ~~comprising administering to the patient a composition comprising~~ wherein the medicament is for intravitreal injection at a dose of about 1 mg to about 10 mg ~~of an anti-C1q antibody via an intravitreal injection~~, and

wherein the antibody comprises a light chain variable domain comprising an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7; and a heavy chain variable domain comprising an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.

2. The ~~method~~ use of claim 1, wherein the antibody comprises a light chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 4 and 35-38 and wherein the light chain variable domain comprises an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7.

3. The ~~method~~ use of claim 2, wherein the light chain variable domain compris~~es~~~~ing~~ an amino acid sequence selected from SEQ ID NO: 4 and 35-38.

4. The ~~method~~ use of any one of claims 1-3, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 8 and 31-34 and wherein the heavy chain variable domain comprises an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.

5. The ~~method~~ use of claim 4, wherein the heavy chain variable domain compris~~es~~~~ing~~ an amino acid sequence selected from SEQ ID NO: 8 and 31-34.

6. The ~~method~~ use of any one of claims 1-5, wherein the antibody is a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, an antibody fragment, or antibody derivative thereof.

7. The ~~method~~ use of claim 6, wherein the antibody is an antibody fragment and the antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

8. The ~~method~~ use of claim 7, wherein the Fab fragment comprises a heavy chain Fab fragment of SEQ ID NO: 39 and a light chain Fab fragment of SEQ ID NO: 40.

9. The ~~method~~ use of any one of claims 1-8, wherein the ~~antibody is administered~~ medicament is for administration once a week, ~~.~~

~~10. The method of any one of claims 1-8, wherein the antibody is administered~~ once every other week, ~~.~~

~~11. The method of any one of claims 1-8, wherein the antibody is administered~~ once every three weeks, ~~.~~

~~12. The method of any one of claims 1-8, wherein the antibody is administered~~ once a month, ~~.~~

~~13. The method of any one of claims 1-8, wherein the antibody is administered~~ once every four weeks, ~~.~~

~~14. The method of any one of claims 1-8, wherein the antibody is administered~~ once every six weeks, ~~.~~

~~15. The method of any one of claims 1-8, wherein the antibody is administered~~ once every 8 weeks, ~~.~~

~~16. The method of any one of claims 1-8, wherein the antibody is administered~~ once every other month, ~~.~~

~~17. The method of any one of claims 1-8, wherein the antibody is administered~~ once every 10 weeks~~,~~ .

~~18. The method of any one of claims 1-8, wherein the antibody is administered~~ once every 12 weeks~~,~~ .

~~19. The method of any one of claims 1-8, wherein the antibody is administered~~ once every three months, or ~~,~~ .

~~20. The method of any one of claims 1-8, wherein the antibody is administered~~ once every 4 months.

~~21~~10. The ~~method~~ use of ~~any one of claims 9-20~~claim 9, wherein the medicament is for administration ~~antibody is administered~~ for at least 3 months, at least 4 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.

~~22~~11. The ~~method~~ use of ~~any one of claims 9-21~~claim 9 or 10, wherein the medicament is for administration ~~antibody is administered~~ for 12 months.

~~23~~12. The ~~method~~ use of any one of claims 1-~~22~~11, wherein the ~~administered composition~~dose comprises about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of the anti-C1q antibody.

~~24~~13. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the ~~composition~~ dose comprises ~~administering~~ about 1 mg of the anti-C1q antibody.

~~25~~14. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the ~~composition~~ dose comprises ~~administering~~ about 2.5 mg of the anti-C1q antibody.

~~26~~15. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the ~~composition~~ dose comprises ~~administering~~ about 5 mg of the anti-C1q antibody.

~~27~~16. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the dose ~~composition~~ comprises ~~administering~~ about 2 mg of the anti-C1q antibody.

~~28. The method of any one of claims 1-23, wherein the composition comprises administering about 5 mg of the anti-C1q antibody.~~

~~29~~17. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the dose ~~composition~~ comprises ~~administering~~ about 10 mg of the anti-C1q antibody.

~~30~~18. The ~~method~~ use of any one of claims 1-~~23~~12, wherein the dose ~~composition~~ comprises ~~administering~~ about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, or about 7.5 mg to about 10 mg of the anti-C1q antibody.

~~31~~19. The ~~method~~ use of any one of claims 1-~~30~~18, wherein the ocular disease is glaucoma or age-related macular degeneration.

~~32~~20. The ~~method~~ use of claim ~~31~~19, wherein the age-related macular degeneration is geographic atrophy.